Intellia Therapeutics, Inc. (NTLA) Stock Price & Analysis
Intellia Therapeutics, Inc. (NTLA) fell 4.45% to USD 12.89 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.
NTLA last closed at USD 13.49; the session ranged USD 12.54–14.25 on volume of 5,623,029 shares. Market capitalization is $1.80B, with a 52-week range of USD 7.95–28.25 (NGM). Source: Nexqual, June 9, 2026 at 23:49 UTC.
Key Statistics (as of June 9, 2026 at 23:49 UTC)
| Price | USD 12.89 |
|---|---|
| Change | ▼ 4.45% (down) |
| Previous Close | USD 13.49 |
| Open | USD 13.77 |
| Day Range | USD 12.54 – 14.25 |
| 52-Week Range | USD 7.95 – 28.25 |
| Volume | 5,623,029 shares |
| Market Cap | $1.80B |
| Exchange | NGM |
Technical Analysis (NTLA)
Nexqual's technical model rates NTLA "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.3 (neutral) |
| vs SMA50 | Below (USD 13.65) |
| MACD | -0.03 (negative) |
Analyst Ratings (NTLA)
Wall Street analysts rate NTLA "Buy" based on 19 analysts, with a mean price target of USD 26.63 (range USD 8–95), per Nexqual as of June 9, 2026 at 23:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 26.63 |
| High Target | USD 95 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 12 / 9 / 2 |
Earnings (NTLA)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.8 |
| Revenue Estimate | $13.18M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.81 vs est -0.9 ▲ beat |
| 2025-12-31 | USD -0.83 vs est -0.96 ▲ beat |
| 2025-09-30 | USD -0.92 vs est -1 ▲ beat |
| 2025-06-30 | USD -0.98 vs est -1.01 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financials & Fundamentals (NTLA)
| Total Revenue | $66.09M |
|---|---|
| Revenue Growth (YoY) | -9.50% |
| Gross Margin | +0.00% |
| Operating Margin | -668.07% |
| Profit Margin | +0.00% |
| ROE | -56.34% |
| Debt / Equity | 12.96 |
| Current Ratio | 6.1 |
| Total Cash | $375.99M |
| Total Debt | $80.49M |
| Free Cash Flow | $-235.23M |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financial Health Score (NTLA)
Nexqual rates Intellia Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:49 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $376M cash vs $80M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$235M, burning cash |
| Efficiency | Critical — ROE -56%, ROA -30.1% |
Ownership (NTLA)
| Insider Ownership | +3.83% |
|---|---|
| Institutional Ownership | +76.74% |
| Shares Outstanding | 139.72M |
| Float | 134.16M |
| Short % of Float | +46.78% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Leadership (NTLA)
Intellia Therapeutics, Inc. is led by John M. Leonard (age 68), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:49 UTC.
| President, CEO & Director | John M. Leonard (age 68) |
|---|---|
| Executive VP, CFO & Treasurer | Edward J. Dulac (age 49) |
| Executive VP & Chief Scientific Officer | Birgit Schultes (age 62) |
Major Backers & Investors (NTLA)
Notable institutional backers of Intellia Therapeutics, Inc. include ARK Invest, Shaw D.E. & Co., Inc., Two Sigma Investments, LP, according to Nexqual as of June 9, 2026 at 23:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 21.13% |
| Shaw D.E. & Co., Inc. | 4.1% |
| Two Sigma Investments, LP | 3.37% |
| Regeneron Pharmaceuticals Inc | 2.65% |
| Fidelity | 2.3% |
| UBS Group AG | 1.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.67% |
| BlackRock | 10.58% |
| State Street | 7.95% |
| Geode Capital | 2.04% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
From Intellia Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We aim to remain a pioneer in the field by developing additional product candidates that leverage our proprietary technologies acquired or developed over a decade-plus of research and development, including multi-modal CRISPR gene editing, LNP, and oligonucleotide technologies. 6   Collaborate with partners to expand the reach of our technology and maximize our return on investment.
- The potential application of our proprietary technologies, including CRISPR gene editing, is extremely broad, and we plan to continue to identify partners who can contribute meaningful resources and insights to our programs and allow us to more rapidly bring scientific innovation to a broader patient population.
- Our Pipeline The following table summarizes the status of our research and development programs: Lead Programs We are the first company to advance in vivo genome editing product candidates into Phase 3 development.
- Collaborations and Other Arrangements To accelerate the development and commercialization of therapeutic products that use our proprietary technologies in multiple therapeutic areas, we have formed, and intend to seek other opportunities to form, strategic alliances with collaborators who can augment our leadership in the development of therapeutic products.
Partnerships
- Strategy Our strategy is to (1) advance the clinical development of our lead CRISPR-based product candidates, (2) build and leverage a fully integrated commercial-stage infrastructure, (3) expand our pipeline utilizing our expertise and proprietary technologies, and (4) collaborate with partners to expand our technology reach and maximize our return on investment.
- Regeneron Pharmaceuticals, Inc. ("Regeneron") In April 2016, we entered into a license and collaboration agreement with Regeneron (as amended from time to time, the "2016 Regeneron Agreement").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EDIT | Editas Medicine, Inc. | USD 2.65 | ▼ 2.21% |
| CRSP | CRISPR Therapeutics AG | USD 51.48 | ▼ 0.69% |
| BEAM | Beam Therapeutics Inc. | USD 30.47 | ▲ 3.64% |
| PACB | Pacific Biosciences of Californ | USD 1.37 | ▼ 5.52% |
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.